Author: admin

Torrejón Hospital completed the staffing of the Digital image diagnostic service.

|

El Torrejón Hospital full staffing of the diagnostic service for the Digital image.

the Center, which will open its doors after the summer, install latest digital equipment for ultrasound and mammography.

-the new Center will feature a drive of diagnosis breast

-the hospital already has two TAC and a magnetic resonance

Madrid, August of 2011- the Hospital of Torrejón Ardoz of the community of Madrid has completed the technological strength of its diagnostic imaging area. The main feature of this service is that it is completely digital. “ Diagnostic tests to be undertaken for patients are in digital format, which provides a better quality of image diagnosis and can be much more agile to put at the disposal of the medical test image ”, explained Ignacio Martinez Jover, managing director of the Hospital of Torrejón.

Past teams to join the Centre have been the scanners and digital mammograms. In this way, Hospital Torrejón, has completed technology staffing of the Centre, with all the digitized Radiology.

Digital radiology allows patients are exposed to fewer levels of radiation in case of having to repeat the test, resulting in better care, while the quality of the digital image exceeds the conventional, providing more useful for the diagnosis of the specialist information.

Digital ultrasound is a procedure of diagnostic imaging that uses ultrasonic emission to provide images of the information can be used in part or in its entirety without the need to cite sources inside the human body. It is a completely safe technology, which does not emit radiation and provides very useful information to know the State of health of patients.

Mammography is an exploration of diagnostic breast of patients through x-ray to achieve the highest level of information about the internal structure of the mammary gland. This diagnostic technology is especially useful for detecting lesions in very small sizes, so it has become an ally of first level in tackling early mammary pathology. As it cannot be otherwise, the diagnosis early associated in almost all cases with a higher rate of healing.

The Torrejon Hospital completes the strength of his unit of diagnostic breast, encompassing all the technologies that are used for the care, diagnosis and treatment of mammary pathology.

Read More

“Patients with a transplanted kidney, has better quality of life, but should not be forgotten as a patient and must take care with care their health.”

|

“ The patient with a transplanted kidney, has better quality of life, but must not forget his sick condition and must take care with care their health ”.

almost 100 experts in dialysis and transplants met in Granada to discuss the present and future of chronic kidney disease. According to the Spanish society of dialysis and transplant (SEDYT) increasingly is diagnosed earlier and better kidney disease.

-Congress will analyse the nutrition in patients on dialysis and prior to kidney transplantation care

– will be discussed on the present and future of hemodialysis and peritoneal dialysis and transplants, especially live

– patient data updated in 2010 with chronic kidney diseasehemodialysis and dialysis, and transplanted in Spain, Andalusia and Granada

Spain, 2011-may the Dr. Julen Ocharan, President of the Spanish society of dialysis and transplantation, and President of the Scientific Committee of the Congress XXXIII SEDYT believes that “ the transplanted patient is a success in chronic kidney disease but should not be forgotten that it is of a patient in which renal develops it only one kidney, should therefore take care of it and must take care. It should continue with a healthy lifestyle, monitoring food and take medication for the care of the kidney with rigorous ”.

This will be one of the ideas to be dealt with in the XXXIII Congress of SEDYT that according to Dr. José Hervás, President of the Congress “ wants to be a new point of encounter and discussion for top professionals in our country in the field of dialysis and kidney transplantation. We must not forget that in Spain currently there are 40,000 patients with chronic kidney disease who need kidney replacement therapy, i.e. dialysis ”.

Congress begins on Wednesday May 11 hours in Nephrology nursing, a space so that nurses and optional can share knowledge environment for dialysis. The new challenges and new tasks of the Nephrology nursing, with special attention to food will explore. Malnutrition is one of the first consequences of dialysis patients, who must also control the consumption of nutrients such as phosphorus or potassium, if they are not correctly filtered can cause very serious diseases.

Thursday, may 12, the debates rotate on dialysis. We will analyze the present and future prospects of hemodialysis and peritoneal dialysis, techniques that have a different impact on the quality of life of the patient. Hemodialysis was the first system devised to replace the cleaning function that does not make one sick kidney, still today the technique most commonly used in Spain in the treatment of patients with chronic kidney disease. Also discuss new advances in Nephrology therapy according to Dr. José Hervás, President of the Congress “ allow for a better quality of life and survival in these patients, which are reduced their quality of life at the time that must connect to a machine ”. The new basic guidelines for clinical practice of the Spanish society of dialysis and transplant (SEDYT) will also be presented to ensure the protocolarización of the treatment of this disease and to ensure adequate care to the patient.

Friday 13, last day of the Congress, will be dedicated to transplants, with particular emphasis on transplantation of live, which will give details the Dr. Antonio Osuna in the Hospital Universitario Virgen de las Nieves of Granada and Dr. Rafael Matesanz, director of the national transplant organisation.

Terminology help

Kidney and liver are the two scrubbers organs of our body. Renal replacement therapy may be the transplant and dialysis (which in turn may be hemodialysis or peritoneal dialysis).

Dialysis: is the medical term used to define the artificial process of filtration of waste products and the Elimination of excess fluids of the body at the time in which the kidneys cannot be it normally.

Hemodialysis: Is a type of dialysis. It was the first technique that was used in Spain and remains the most widely used. Currently 90% of kidney patients using hemodialysis. A complex in a vein puncture is performed that can leave the blood cleaned through an external circuit through a machine. Patients requiring hemodialysis often performed in a hospital or specialized Centre. Go about 3 or 4 days a week and are about 4 hours in each session.

Peritoneal dialysis: is another technique of dialysis. It is used as a natural membrane filter – peritoneum – internally lining the abdominal cavity of the patient. Requires a small surgical procedure in which a catheter is inserted in the stomach, through it is the exchange of fluids, either manual or mechanized. This type of dialysis is always home, and allows a greater autonomy of the patient.

Read More

International Myeloma Foundation: a study shows that long term maintenance therapy demonstrates an overall survival rate of 90%.

|

International Myeloma Foundation: one study noted that long-term maintenance therapy demonstrates an overall survival rate of 90%.

Madrid, 2011-may the Foundation International of myeloma (IMF), the most ancient and important foundation dedicated to the improvement of life and care for myeloma patients, said on Thursday that new data show that maintenance therapy with REVLIMID (R) (the Celgene biopharmaceutical company) after the transplantation of cells (bone marrow) mother delay time to disease progression and improves survival in general. The figures for the study of the B group of cancer and leukemia (CALGB), sponsored by the Instituto Nacional of the cancer of United States, have demonstrated a survival rate of 90% in the branch of REVLIMID trial after more than two years after the transplant in comparison to the survival rate of 83% of patients who received placebo *. The study also showed that the maintenance with REVLIMID resulted in revisions to longer, delaying the progression of the disease by an average of four years. These findings were presented at the 13th annual international the Myeloma Workshop in Paris

“ This clearly validates an important treatment option for patients ”, points out Dr. Kenneth Anderson, of Cancer Institute Dana-Farber. “ The development of new dedicated drugs, such as REVLIMID, that are well tolerated, has allowed us to take account of this approach, and with these new survival data of long-term maintenance can add to our arsenal as a new standard of care ”.

Terry Barter, a patient of Dr. Anderson, was included in one of the first clinical trials of the REVLIMID, and still continues to take the drug almost ten years later: “ I ride my motorcycle, I’m going to work every day, I have energy, almost do not have side effects. It has simply been a drug for me ”.

A similar study on REVLIMID after the transplant, the French myeloma francophone Intergroup (IFM) also shows benefits in the progression of the disease-free survival, patients who live longer without it manifests in an active way. And considering the maintenance as an option with other drugs including VELCADE ® when administered in low doses, or as a subcutaneous injection rather than the traditional intravenous.

There is a problem with a small number of second cancers that develop in patients taking REVLIMID in the long term. Possible factors, including genetic profiles and previous treatments of the patients being studied.

“ There is a risk/benefit relationship in all of the powerful medications, but overall survival shows clearly that in this case, the benefits offset to spare any risk ”, says Dr. Brian G.M. Durie, Chairman of the IMF, who is co-author of a retrospective analysis of REVLIMID and second cancers was also presented at the Conference.

Myeloma, also known as multiple myeloma is a cancer that affects the cells in the bone marrow and blood can cause damage to the bone. It has no cure.

*(p_no_ajustada_>0,018)

about the International Foundation of myeloma

the International Myeloma Foundation is the Organization of the myeloma oldest and largest, with more than 195,000 members from 113 countries around the world. Organization non-profit dedicated to improving the quality of life for their families, the IMF and myeloma patients focuses on four key areas: research, education, support and defence. To date, the IMF has held more than 200 educational seminars around the world, maintains a line of help of world-renowned and managed Bank on a Cure ®, unique genetic Bank used to advance myeloma research.

Read More

VerifyNow P2Y12 test gets the EC brand new prognosis.

|

VerifyNow P2Y12 test gets the EC brand new prognosis.

-test of Accumetrics platelet reactivity gets CE mark for identification of patients at high risk of recurrent cardiovascular events

San Diego, may of 2011. Accumetrics, Inc., developer of the system VerifyNow (R), the first medical system fast and easy to use for the measurement of the revival of platelets to multiple antiplatelet agents, announced last Tuesday that VerifyNow P2Y12 test has already received the CE mark for its use of prognosis in the identification of patients with residual platelet reactivity high (also to) (those who have submitted a poor response) in anti-platelet therapies (e.g. clopidogrel) who are at high risk of future cardiovascular events.

There are numerous studies that have demonstrated the connection between highly residual platelet reactivity and the great risk of ischemic events. Studies have been more than 3,000 patients, who used the test VerifyNow P2Y12, showing the correlation between clinical outcomes based on the PRUDENT (P2Y12 reaction units) results, reaching the conclusion that treatment PRUDENT greater than or equal to 230 identifies patients at risk much higher future cardiovascular eventsincluding death, stent thrombosis and heart attack.

“Researchers, like me, have long been studying the relationship between platelet reactivity while undergoing therapy against platelet and risk of recurrent ischemic events within our cardiovascular patients”, said Robert d. Storey, doctor and Professor of cardiology at the University of SheffieldEngland. “The VerifyNow P2Y12 test offers a quick and easy means to assess the individual response to platelet drugs.” “The achievement of a claim of prognosis will strengthen the application of risk stratification, potentially to guide therapy in the patients ometidos coronary stent to”.

“The CE mark for use in prognosis of VerifyNow P2Y12 test in high risk assessment represents an achievement highlighted to Accumetrics,” said Timothy i. Still, managing director and CEO of ccumetrics. “In addition, considering the recent inclusion of the evidence of eactividad of platelet in UA/NSTEMI ACCF/AHA guidelines and guidelines for the conservation of the STS/SCA, VerifyNow system blood has resulted in a considerable mpacto on how physicians treat cardiovascular patients”.

VerifyNow system is widely used in several clinical settings in which anti-platelet medications are prescribed to reduce the occurrence of future episodes thrombotic attacks and heart stoppages. VerifyNow P2Y12 test is not currently indicated for use in assessment of risk in United States cases. The EC mark of this use is recognized by the European economic area.

About Accumetrics

Accumetrics is committed to the advancement of medical knowledge of the role of platelets and the improvement of the quality in the treatment of patients who receive anti-platelet therapies, providing test diagnosis widely accessible for rapid assessment of platelet function and leaders in the industry.

Accumetrics VerifyNow system is the first platform quick and easy to use that he helps doctors to evaluate the individual response of multiple antiplatelet agents. It is aimed at leading antiplatelet drugs, including products approved by the FDA for aspirin, inhibitors P2Y12 (for example, prasugrel (Effient (R)) and clopidogrel (Plavix (R)), and inhibitors GP IIb/IIIa (for example, ReoPro (R) and Integrilin r), the system VerifyNow provides a valuable tool to help doctors decide on treatment with higher basis.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips